Claims for Patent: 12,083,112

Summary for Patent: 12,083,112

Title:	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
Abstract:	The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
Inventor(s):	Andrew Evan DENKER, Yu Kato, Kimiyo Tabata, Yusaku Hori
Assignee:	Eisai R&D Management Co Ltd , Merck Sharp and Dohme LLC
Application Number:	US17/502,962
Patent Claims:	1. A method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a multiple receptor tyrosine kinase (multi-RTK) inhibitor, wherein the PD-1 antagonist is pembrolizumab, and wherein the multi-RTK inhibitor is lenvatinib or a pharmaceutically acceptable salt thereof, and wherein the cancer is thyroid cancer, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), endometrial cancer, squamous cell carcinoma of head and neck, glioblastoma, gastric cancer or melanoma. 2. The method of claim 1, wherein the individual is a human. 3. The method of claim 1, wherein the combination therapy which comprises pembrolizumab and lenvatinib or a pharmaceutically acceptable salt thereof is administered after an administration of lenvatinib or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the combination therapy which comprises pembrolizumab and lenvatinib or a pharmaceutically acceptable salt thereof is administered after an administration of lenvatinib or a pharmaceutically acceptable salt thereof for at least 7 days. 5. The method of claim 1, wherein the combination therapy which comprises pembrolizumab and lenvatinib or a pharmaceutically acceptable salt thereof is administered after an administration of pembrolizumab. 6. A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-1), the second container comprises at least one dose of a medicament comprising a multi-RTK inhibitor, and the package insert comprises instructions for treating an individual for cancer using the medicaments, wherein the PD-1 antagonist is pembrolizumab, and wherein the multi-RTK inhibitor is lenvatinib or a pharmaceutically acceptable salt thereof. 7. The kit of claim 6, wherein the instructions state that the medicaments are intended for use in treating an individual having a cancer that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay. 8. The kit of claim 6, wherein the individual is a human. 9. The kit of claim 6, wherein the antagonist is pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5, and the multi-RTK inhibitor is lenvatinib or a pharmaceutically acceptable salt thereof formulated as a 4 mg or 10 mg lenvatinib capsule comprising calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc. 10. The kit of claim 6, wherein the cancer is thyroid cancer, HCC, NSCLC, RCC, endometrial cancer, squamous cell carcinoma of head and neck, glioblastoma or melanoma. 11. A method for treating a human individual diagnosed with a cancer, comprising administering to the individual a combination therapy for at least 24 weeks, wherein the combination therapy comprises pembrolizumab and lenvatinib or a pharmaceutically acceptable salt thereof, wherein lenvatinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of 24 mg, 20 mg or 14 mg, each as lenvatinib, and pembrolizumab is administered at a dose of 200 mg once every three weeks. 12. The method of claim 1, wherein the lenvatinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of 24 mg, 20 mg or 14 mg, each as lenvatinib. 13. The method of claim 1, wherein pembrolizumab is administered at a dose of 200 mg once every three weeks. 14. The method of claim 1, wherein the cancer is thyroid cancer. 15. The method of claim 1, wherein the cancer is HCC. 16. The method of claim 1, wherein the cancer is RCC. 17. The method of claim 1, wherein the cancer is endometrial cancer. 18. The method of claim 1, wherein the cancer is squamous cell carcinoma of head and neck. 19. The method of claim 1, wherein the cancer is glioblastoma. 20. The method of claim 1, wherein the cancer is gastric cancer. 21. The method of claim 1, wherein the cancer is melanoma.